Apellis Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$46.7M
Doctors Paid
7,057
Transactions
25,951
2024 Total
$12.7M
Payment Breakdown by Category
Research$36.8M (78.7%)
Consulting$4.0M (8.5%)
Food & Beverage$814,370 (1.7%)
Travel$502,890 (1.1%)
Royalty/License$57,913 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $36.8M | 5,115 | 78.7% |
| Consulting Fee | $4.0M | 841 | 8.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.7M | 840 | 7.8% |
| Food and Beverage | $814,370 | 17,268 | 1.7% |
| Honoraria | $509,374 | 262 | 1.1% |
| Travel and Lodging | $502,890 | 1,218 | 1.1% |
| Grant | $313,047 | 8 | 0.7% |
| Space rental or facility fees (teaching hospital only) | $90,450 | 28 | 0.2% |
| Royalty or License | $57,913 | 1 | 0.1% |
| Education | $9,521 | 370 | 0.0% |
Payments by Type
Research
$36.8M
5,115 transactions
General
$9.9M
20,836 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD | $17.7M | 0 | 2,423 |
| A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration | $4.5M | 0 | 488 |
| Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration | $3.3M | 0 | 446 |
| A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | $2.4M | 0 | 1,110 |
| A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First In Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of APL3007 in Healthy Adult | $1.6M | 0 | 9 |
| Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis | $1.1M | 0 | 107 |
| GALE | $788,941 | 0 | 92 |
| Pegcetacoplan Long Term Safety and Efficacy Extension Study | $348,066 | 0 | 52 |
| Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies | $335,180 | 0 | 33 |
| Oaks | $293,294 | 0 | 80 |
| Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN | $258,356 | 0 | 33 |
| MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) | $253,328 | 0 | 53 |
| Characterization of the Progression of AMD Geographic Atrophy in Clinical Practice | $201,700 | 0 | 1 |
| Derby | $192,278 | 0 | 51 |
| Growth Modeling for Quantitative, Spatially-Resolved Geographic Atrophy Lesion Kinetics | $163,242 | 0 | 3 |
| Screening for dry AMD | $68,600 | 0 | 2 |
| Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) | $49,615 | 0 | 19 |
| Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy | $45,214 | 0 | 7 |
| LTSE | $44,773 | 0 | 9 |
| MERIDIAN | $33,567 | 0 | 7 |
| APL-COV-201 | $29,039 | 0 | 4 |
| Plaudit | $19,465 | 0 | 4 |
| Pegasus | $15,787 | 0 | 2 |
| A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | $10,575 | 0 | 11 |
| Valiant | $9,950 | 0 | 1 |
| Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | $9,422 | 0 | 3 |
| A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 | $4,922 | 0 | 2 |
| n/a | $2,444 | 0 | 1 |
| Discovery | $1,226 | 0 | 1 |
| NOBLE | $204.00 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Sandra Richman, M.d, M.D | Internal Medicine | Brookline, MA | $430,550 | $0 |
| Kuldev Singh, Md, MD | Ophthalmology | Stanford, CA | $272,143 | $0 |
| Rishi Singh, Md, MD | Ophthalmology | Boston, MA | $256,413 | $0 |
| Dr. Dilsher Dhoot, M.d, M.D | Retina Specialist | Santa Barbara, CA | $255,171 | $0 |
| Ehsan Rahimy, Md, MD | Ophthalmology | Stanford, CA | $220,670 | $0 |
| Dr. Jonathan Jonisch, Md, MD | Ophthalmology | Great Neck, NY | $205,241 | $0 |
| Dr. Roger Goldberg, Md, MD | Ophthalmology | Walnut Creek, CA | $204,495 | $0 |
| Dr. Nathan Steinle, M.d, M.D | Ophthalmology | Santa Barbara, CA | $171,259 | $0 |
| David Eichenbaum, M.d, M.D | Retina Specialist | St Petersburg, FL | $154,042 | $0 |
| Charles Wykoff, Md, Phd, MD, PHD | Retina Specialist | Bellaire, TX | $152,713 | $0 |
| Michael Singer, M.d, M.D | Ophthalmology | San Antonio, TX | $132,828 | $0 |
| Dr. Ankur Shah, M.d, M.D | Retina Specialist | Carmel, IN | $125,872 | $0 |
| Joseph Coney, M.d, M.D | Ophthalmology | Beachwood, OH | $120,556 | $0 |
| Dr. David Chin Yee, Md, MD | Retina Specialist | Atlanta, GA | $116,738 | $0 |
| Dr. Caroline Baumal, Md, MD | Specialist | Boston, MA | $116,210 | $0 |
| Dr. Jorge Fortun, Md, MD | Ophthalmology | Palm Beach Gardens, FL | $108,067 | $0 |
| Dr. Jeremy Wolfe, Md, MD | Ophthalmology | Royal Oak, MI | $95,568 | $0 |
| Brian Mulherin, M.d, M.D | Medical Oncology | Indianapolis, IN | $86,904 | $0 |
| Dr. Jordana Fein, M.d., M.s, M.D., M.S | Ophthalmology | Manassas, VA | $85,381 | $0 |
| Dr. Ivan Suner, M.d, M.D | Ophthalmology | Tampa, FL | $83,846 | $0 |
| Dr. Howard Fine, Md Mhsc, MD MHSC | Ophthalmology | New Brunswick, NJ | $83,201 | $0 |
| Murtaza Adam, Md, MD | Ophthalmology | Parker, CO | $75,315 | $0 |
| Dr. Caroline Piatek, M.d,, M.D, | Internal Medicine | Los Angeles, CA | $74,416 | $0 |
| Carl Regillo, Md, MD | Ophthalmology | Plymouth Meeting, PA | $72,205 | $0 |
| Dr. John Kitchens, M.d, M.D | Ophthalmology | Lexington, KY | $71,250 | $0 |
About Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. has made $46.7M in payments to 7,057 healthcare providers, recorded across 25,951 transactions in the CMS Open Payments database. In 2024, the company paid $12.7M. The top product by payment volume is Syfovre ($3.7M).
Payments were distributed across 94 medical specialties. The top specialty by payment amount is Ophthalmology ($4.3M to 2,598 doctors).
Payment categories include: Food & Beverage ($814,370), Consulting ($4.0M), Research ($36.8M), Travel & Lodging ($502,890), Royalties ($57,913).
Apellis Pharmaceuticals, Inc. is associated with 4 products in the CMS Open Payments database, including Syfovre, Empaveli, and EMPAVELI.